Pulsed Electromagnetic Fields for Clinical Applications
59,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
30 °P sammeln
  • Broschiertes Buch

This book presents the historical development, the state of art and the future of the application of PEMF for treatment of various medical problems. In perspective, this modality provides a practical, exogenous method for inducing cell and tissue modification attempted to return the injured tissues to their normal physiological status.

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book presents the historical development, the state of art and the future of the application of PEMF for treatment of various medical problems. In perspective, this modality provides a practical, exogenous method for inducing cell and tissue modification attempted to return the injured tissues to their normal physiological status.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Marko S. Markov received his BS, MS and PhD from Sofia University, Bulgaria. He has been Professor and Chairman of the Department of Biophysics and Radiobiology at Sofia University for 22 years. He had been invited professor and lecturer in a number of European, Japanese and American academic and industry entities. For the years his research was on biological and clinical studies of the effects of various electromagnetic fields. He is a founder and member of the Editorial board of the journal "Electromagnetic biology and medicine". He has ben author and co-author of more that 200 peer-reviewed papers. Dr. Markov is author, editor and co-editor of 26 books, published by Plenum Press, Springer, Marcel Dekker and CRC. His book "Electromagnetic fields in biology and medicine" published by CRC Press is being translated on mandarin in China. Jim Ryaby, PhD joined Orthofix as Chief Scientific Officer in July 2013 after serving as a consultant. Before joining the Company, he served as Vice President of Research and Clinical Affairs for musculoskeletal applications at Mesoblast. Dr. Ryaby has also held the position of Senior Vice President of Research and Clinical Affairs and Chief Scientific Officer at OrthoLogic Corp in Tempe, AZ. where he led the development of the CMF technology for spine fusion and nonunions and the TP508 peptide therapeutic development program in orthopedic and diabetic ulcer applications. Additionally, he has served as Adjunct Professor of Bioengineering at Arizona State University. Dr. Ryaby received his PhD degree in cellular and molecular biology from the Mt. Sinai School of Medicine, New York. Erik I. Waldorff, PhD, is the Principal Scientist and Research Manager for the orthopedic medical device company, Orthofix, which he joined in 2012. Prior to this Dr. Waldorff served as a Clinical Research Scientist for the Neuromodulation Division at St. Jude Medical (now Abbott) where he performed pre-clinical studies in addition to post-market clinical trials for spinal cord stimulation and deep brain stimulation patients. In addition following his doctoral studies, Dr. Waldorff held a position as a Postdoctoral Fellow at the Michigan Institute for Clinical and Health Research (MICHR) at the University of Michigan where he led orthopaedic human and animal studies. Dr. Waldorff received his PhD and MSE degrees in Biomedical Engineering and MSE and BSE degrees in Aerospace Engineering from the University of Michigan (Ann Arbor, Michigan).